121 results about "TB - Tuberculosis" patented technology

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

The invention provides a method of diagnosing tuberculosis (TB) in a test subject, said method comprising: (i) providing expression data of two or more markers in a subject, wherein at least two of said markers are selected from transthyretin, neopterin, C-reactive protein (CRP), serum amyloid A (SAA), serum albumin, apoliopoprotein-A1 (Apo-A1), apolipoprotein-A2 (Apo-A2), hemoglobin beta, haptoglobin protein, DEP domain protein, leucine-rich alpha-2-glycoprotein (A2GL) and hypothetical protein DFKZp667I032; and (ii) comparing said expression data to expression data of said marker from a group of control subjects, wherein said control subjects comprise patients suffering from inflammatory conditions other than TB, thereby determining whether or not said test subject has TB.

The invention discloses a polypeptide composition which is formed by combining an antigen Mtb16.3, an antigen 38kD, ESAT-6, CFP 10, MPT 64, Mtb 8 and Mtb 8.4. The antigens Mtb 16.3, 38kD, ESAT-6, CFP 10 and MPT 64 have excellent complementarities in serological detection. The sensitivity for diagnosing tuberculosis is obviously promoted by combining antigen Mtb16.3 with at least one of antigen 38kD, ESAT-6, CFP 10 and MPT 64.

The present invention relates to a gamma-interferon sandwich ELISA detection method based on recombinant fusion antigen protein, further relates to a recombinant fusion antigen protein preparation method and a gamma-interferon monoclonal antibody preparation method, and belongs to the technical field of medical examination determination. According to the present invention, the recombinant fusion antigen protein is formed by linking secretory antigen protein MPB70, antigen protein CFP10 and antigen protein ESAT6 through peptide bonds, the gamma-interferon monoclonal antibody is prepared through immunization of animals, cell fusion, hybridoma cell screening, cloning and purification, and the recombinant fusion antigen protein and the gamma-interferon monoclonal antibody are adopted to establish a sandwich ELISA detection method; and the recombinant fusion antigen protein can rapidly stimulate a bovine blood sample to secret gamma-interferon, and the gamma-interferon monoclonal antibody can quickly and specifically identify bovine gamma-interferon, such that strong sensitivity and strong specificity are provided, and broad application prospects are provided in the field of buffalo tuberculosis diagnosis.

This invention relates to the detection and diagnosis of tuberculosis. More specifically, the invention relates to new biomarkers and combinations thereof that enable the accurate detection and diagnosis of tuberculosis.

The invention discloses application of PRDM1 as a marker for preparing a product for diagnosing active tuberculosis. Fluorescence quantitative PCR is adopted for detecting expression quantity of a PRDM1 gene in a tuberculosis patient PBMCs. A result shows that the relative expression quantity of PRDM1 in smear positive tuberculosis patients, smear negative tuberculosis patients and extrapulmonarytubereulosis patients PBMCs is remarkably lowered that that of latent tuberculosis infected persons and healthy control. A subject working characteristic curve analysis result shows that PRDM1 can distinguish active tuberculosis and latent tuberculosis infection, and becomes the diagnosis target for diagnosing the active tuberculosis.

The invention discloses application of RETN and KLK1 serving as tuberculosis detecting markers. Experiments prove that the RETN gene and the KLK1 gene have evident expression differences in normal tissue, the tissue of a person with latent tuberculosis infection (LTBI) and the tissue of a patient with tuberculosis (TB), the expression level of the RETN gene in the tissue of the patient with tuberculosis (TB) is much higher than that in the normal tissue or in the tissue of the person with latent tuberculosis infection (LTBI), and the expression level of the KLK1 gene in the tissue of the patient with tuberculosis (TB) is much lower than that in the normal tissue or in the tissue of the person with latent tuberculosis infection (LTBI). Therefore, the RETN gene and the KLK1 gene can be usedas the markers for detecting or diagnosing the tuberculosis, and the occurrence and development of the tuberculosis can be monitored.

The invention discloses a catechu extract composition for resisting tubercle bacillus, a preparation method of the catechu extract composition, a pharmaceutical preparation containing the catechu extract composition, and application of the catechu extract composition. The catechu extract composition contains a flavanoid compound of which the purity is more than 50%, and the flavanoid compound takes catechin and / or epicatechin as main components. The main structural formulas (I) and (II) of the flavanoid compound are shown in the specifications, wherein R1, R2, R3, R4 and R5 are respectively and independently selected from hydrogen, C1-C6 alkyl, beta-D-glucopyranesyl, SO3 or PO3. By adopting a chromatographic process for refining and purifying the catechu extract composition disclosed by the invention, the effective content is as high as 99.5%. The catechu extract composition and the pharmaceutical composition thereof have excellent effects on improving or treating pulmonary tuberculosis, treating ulcerative bone tuberculosis and AIDS (Acquired Immune Deficiency Syndrome) complicated by tuberculosis, treating drug resistant tuberculosis, and especially treating drug resistant tuberculosis and AIDS complicated by tuberculosis.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and / or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders / other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.

The invention provides construction of TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand) recombinant bacille calmette guerin (rBCG), and relates to a shuttle expression vector comprising a signal peptide fragment of a major secretory antigen Ag85B of BCG and a gene fragment of a TRAIL and a construction method thereof. The obtained shuttle expression vector pMV261-Ag85B-TRAIL is used for constructing rBCGTRAIL, and can be applied to preparation of TRAIL rBCG for treating superficial bladder tumors, preventing postoperative recurrence thereof and preventing tuberculosis. The rBCG has dual functions of TRAIL and BCG, so that cooperative and synergistic actions of the TRAIL and BCG can be better brought into play; rBCG-TRAIL can secrete TRAIL, and the using amount of the rBCG-TRAIL can be lower than that of the BCG under the condition that the same or better immune effect is achieved, so that the toxic or side effect is reduced; and the rBCG-TRAIL can directly secrete TRAIL efficiently on a certain part, so that tumor cells can be killed in cooperation with the rBCG-TRAIL, and high cost caused by the use of a foreign cell factor is avoided.

The invention relates to a Chinese medicinal soup for treating tuberculosis, diabetes, hypertension, cardiovascular and cerebrovascular diseases, as well as kidney diseases, which is prepared from Siberian solomonseal rhizome, fleece-flower root, bletilla striata, spatholobus stem and glutinous rice through mincing. The soup can be used for breakfast.

The invention discloses protein markers assisting diagnosis of severe secondary pulmonary tuberculosis. The invention provides applications of a product for detecting SOD1 protein, a product for detecting S100A9 protein, a product for detecting ORM2 protein and a product for detecting IL1F6 protein in preparation of a kit used for assisting diagnosis of severe secondary pulmonary tuberculosis. The four protein markers (S100A9, ORM2, IL1F6 and SOD1) assisting diagnosis of the severe secondary pulmonary tuberculosis are found, and a model for assisting diagnosis of the severe secondary pulmonary tuberculosis by utilizing the four protein markers is built. The protein markers provide basis for further explanation of developing and aggravating mechanisms of the secondary pulmonary tuberculosis, provide a novel method and novel indexes for disease development, aggravation early warning, and forecast evaluation, lays a foundation for reasonable treatment and cure of the severe secondary pulmonary tuberculosis, and provides technical supports for reducing the death rate of pulmonary tuberculosis.

Methods of diagnosing and / or monitoring tuberculosis (TB) in a subject by analyzing a test sample comprising at least one volatile organic compound (VOC) or semi-volatile organic compound (SVOC) emitted or excreted from the skin of the subject. The test sample can be analyzed by a sensing unit comprising nanomaterials- and / or polymer-based sensors. Further provided is a skin-mountable device comprising a fixing unit and said sensing unit. Also discloses a method of diagnosing and / or monitoring tuberculosis, comprising analyzing specific skin-emitted VOCs or SVOCs, which are indicative of tuberculosis in a subject.

The present disclosure relates to a method of distinguishing active TB in the presence of a complicating factor, for example, latent TB and / or co-morbidities, such as those that present similar symptoms to TB, such as HIV. The method employs a 27 gene signature to distinguish active tuberculosis from latent TB infection, a 44 gene signature to distinguish active TB from other diseases such as HIV and / or a 53 gene signature to discriminate active TB from latent TB and other diseases. The disclosure also relates to a gene signature employed in the method, a bespoke gene chip for use in the method and a disease risk score obtainable from the method.

The invention relates to an anti-tuberculosis Chinese medicine, a special adjuvant medicine and a preparation method thereof. Pharmaceutically-effective raw materials of the anti-tuberculosis Chinese medicine comprise blister beetle, drgon's bone, oyster, chicken gizzard-membrane, pumice and egg white of 10 eggs (yolk removed). The adjuvant medicine is water soaking liquid or water decoction of one or more selected from milkvetch root, licorice root, ginseng, radix codonopsis, milkvetch root, red jujube and wine-processed twotoothed achyranthes root. The medicine has the effects of removing blood stagnation and eliminating pathogenic accumulation, and is mainly used to treat pulmonary tuberculosis, tuberculous pleurisy, pyogenic osteomyelitis, bone tuberculosis, tuberculosis of thoracic and lumbar vertebra, lymphoid tuberculosis, tuberculous peritonitis, silicosis complicated with tuberculosis, and acute lymphadenitis.

The invention provides an active tuberculosis diagnostic marker, a kit and application thereof. The diagnostic marker is characterized by comprising a blood biomarker MCEMP1 protein in a blood sample,the amino acid sequence of the MCEMP1 protein is as shown in the SEQ ID NO:1. The invention further provides the kit capable of rapidly detecting whether a subject suffers from active tuberculosis ornot. The kit comprises a total RNA extraction related reagent in a whole blood sample, a quantitative PCR related reagent and an ELISA related reagent. According to the active tuberculosis diagnosticmarker, the MCEMP1 is adopted as a biomarker for active tuberculosis detection for the first time, is used for clinical diagnosis and differential diagnosis of tuberculosis, and provides a new direction for clinical diagnosis of tuberculosis.

Disclosed are methods and devices for analyzing aerosol particles in exhaled breath using diagnostic tools that enable rapid, low cost and autonomous point of care assays for several diseases including respiratory tract diseases. Disclosed are methods and devices for capturing exhaled breath aerosols in a packed bed column and analyzing exhaled captured breath aerosols for tuberculosis diagnosis.

The present invention relates to a simple and convenient process for preparing solid lipid sustained release nanoparticles for delivery of drugs / vitamins, preferably fat soluble vitamins and more specifically Vitamin D3 and retinoic acid (RA). The process involves microemulsion technique. The nanoparticles of Vitamin D3 and RA obtained by the process of the present invention have utility in treatment of diseases like tuberculosis. Use may be extended to other diseases like AMD, diabetic retinopathy, cancers, hyperpigmentation, acne, and osteoporosis.

The invention relates to a method for the diagnosis of TB in a subject, the method comprising (a) providing a sample from said subject, said sample being selected from the group consisting of: blood, serum and plasma; (b) determining the concentration in said sample of the following biomarkers: IL-1ra, IL6, IL-7, IL-8, IL-12p70, FGF-basic, IP-10, and VEGF; (c) converting each biomarker concentration determined in (b) into a decile value; and (d) converting each decile value into a binary presence or absence by comparing the decile values of (c) to the following specific quantile cut off values wherein a decile value matching or exceeding the specific quantile cut-off value is converted into the binary presence of the biomarker, and a decile value lower than the specific quantile cut-off value is converted into the binary absence of the biomarker; wherein detecting the presence of each of said biomarkers indicates that the subject has TB. The invention also relates to uses, kits and devices.

The invention discloses an application of system for detecting an ORM1 (orosomucoid 1) gene expression quantity for diagnosing tuberculosis. The application discovers that the ORM1 gene expression quantity has an obvious difference in tuberculosis patients and healthy people; an analysis result of a subject job characteristic curve indicates that the ORM1 gene expression quantity is used for distinguishing that the tuberculosis patients and the healthy people have high sensitivity and specificity, which explains that the tuberculosis can be diagnosed through the detection of the ORM1 gene expression quantity of an object to be detected.

The invention discloses application of S100P protein as a marker in diagnosing active tuberculosis. Compared with a healthy human and a tuberculosis latent infected person, the expression quantity ofS100P gene in PBMCs of an active tuberculosis patient is remarkably increased; the expression quantity of the S100P gene can be used for distinguishing the active tuberculosis patients and the tuberculosis latent infected persons; and the expression quantity of the S100P gene can be used for distinguishing the active tuberculosis patients and the healthy people. Therefore, the S100P protein and / orthe S100P gene can be used as the marker for diagnosing the active tuberculosis. The application has a great application value.

Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof:(relative chemistry shown) pharmaceutical compositions comprising them, their use in therapy especially against tuberculosis, and methods of preparing them are described.

The invention provides a medicine used for treating recurrent pulmonary tuberculosis. The medicine comprises, by weight, 5-12 parts of moxifloxacin, 18-24 parts of p-aminobenzoic isoniazid salicylate, 5-12 parts of rifabutin, 36-45 parts of pyrazinamide, and 18-24 parts of ethambutol. As a result of clinical verification, with the recurrent pulmonary tuberculosis medicine provided by the invention, recurrent pulmonary tuberculosis treatment period can be shortened, and a cure rate can be greatly improved.

The invention discloses a compound arsenical preparation for treating tuberculosis and dermatosis, wherein the weight ratio of the raw materials is orpiment : aresenolite = (0.5-1.5) : (3-5), the preparation also contains right amount of medicinal carrying agent.

The invention discloses a compound paclitaxel anti-tuberculosis capsule tablet preparation method and process, and the process comprises the following steps: step 1, taking a certain amount of paclitaxel extract for dilution, and carrying out separation and passivation treatment on the diluted paclitaxel extract; step 2, carrying out elution treatment on the separated and passivated paclitaxel extract, and carrying out recovery and concentration on the eluted paclitaxel. The paclitaxel anti-tuberculosis capsule tablet has the beneficial effects that the prepared paclitaxel anti-tuberculosis capsule tablet directly kills tubercle bacillus and cancer cell tissues by adopting toxic attack, protects normal cells, is free of toxic reaction, high in curative effect, short in medication time, free of damage to the liver. Meanwhile, the paclitaxel anti-tuberculosis capsule tablet can stimulate and adjust the immune defense function in vivo, enhance the digestion and absorption functions and improve the overall defense function while treating, so that the treatment of tuberculosis is more efficient and safer.

Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof:(relative chemistry shown) pharmaceutical compositions comprising them, their use in therapy especially against tuberculosis, and methods of preparing them are described.